GAIN YOUR MARKET EDGE

Returns since inception - 692.95% 1 year - 116.24%

StockReporter is the ultimate tool for serious investors. Our in-depth market research and stock screening reports help you find the next breakout stock and get ahead of the market.

Profit From +20 Years Trading Experience - Comprehensive Insight
We Utilize Quant Tools for Systematic Screening
In Depth Alerts for Low Risk Small-Mid Caps
Preferred Sectors In Biotech- Tech- Energy- Special Opportunities
NO Penny Stocks, NO Narratives- Only Fundamental / Technical Analysis Using Data

No Bias Only Data

Recent Reports Covering Trending Stocks

Market Gainers / Decliners

Swing Trades - Continuation Patterns

Inverse Conditions For Buying/Selling

Divergence and Money Flow Analysis

Q4 2023 - Click the image to view

Is VIGL Oversold?

Analyst price targets have VIGL upwards of $19.88 which represents +396% from today’s levels.
Vigil Neuroscience, Inc. (NASD: VIGL) is a clinical-stage biotechnology firm focused on the development of neurodegenerative disease therapeutics. Iluzanebart (VGL101), the company's principal product candidate, is a completely human monoclonal antibody agonist of TREM2, a receptor important in regulating brain homoeostasis and synaptic function. Iluzanebart is now being tested in Phase 2 clinical studies for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In addition, the company has a pipeline of preclinical programmes aimed at various neurodegenerative illnesses.
The approach taken by Vigil Neuroscience to finding therapeutics for neurodegenerative illnesses is predicated on the belief that these diseases are caused, at least in part, by malfunctioning of microglia, the brain's resident immune cells. Microglia are important in removing waste and injured cells from the brain, although their activity can be hindered in neurodegenerative illnesses. This can result in the accumulation of harmful proteins, such as amyloid-beta and tau, which are hallmarks of Alzheimer's disease, as well as the death of neurons.
Iluzanebart is intended to stimulate TREM2 and restore microglia function. Iluzanebart has showed promise in preclinical investigations for lowering amyloid-beta and tau accumulation, slowing the course of Alzheimer's disease, and increasing motor function in ALS models. Iluzanebart is now being investigated as a possible treatment for other neurodegenerative illnesses such as Parkinson's and Huntington's.
Current Downtrend
VIGL stock had a strong run in the second part of 2022, but has since faltered this year. Many investors are confused by this current extended downtrend, since clinical achievements and continuous corporate progress aren't always reflected in the share price.
Here are some recent press releases from Vigil Neuroscience Inc (VIGL):
-November 7, 2023: Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
-October 17, 2023: Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease
-October 5, 2023: Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
September 7, 2023: Vigil Neuroscience Presents Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
In their most recent press release, Vigil Neuroscience reported positive interim data from their Phase 2 clinical trial for their ALSP treatment. This news likely drove up the value of VIGL's stock. However, the stock has since fallen back down.
This could be due to a number of factors, including:
Profit-taking: Investors who bought the stock after the positive news may be selling it now to take profits.
Concerns about the long-term efficacy of the treatment: The positive interim data is encouraging, but it is still too early to say whether the treatment will be effective in the long term.
Heavy open short interest which currently sits above 35%
It is crucial to note that these are only a few of the possible factors for the recent drop in VIGL's stock price. Other factors may be at work, and it is always prudent to conduct your own research before making any investing decisions.

According to MarketScreener, the average price target for Vigil Neuroscience Inc (VIGL) is $20.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $24.00, the lowest forecast is $13.00. The average price target represents a 396% increase from the current price of $4.
Here is a table of the analyst price targets for VIGL:
Analyst Price Date
H.C. Wainwright $24.00 November 7, 2023
Oppenheimer $20.00 October 17, 2023
Stifel $13.00 October 5, 2023
As you can see, there is a wide range of analyst price targets for VIGL. This is because there is a lot of uncertainty about the company's future prospects. The company is still in the early stages of development, and its lead product candidate, Iluzanebart (VGL101), is still in clinical trials.
Is a massive short squeeze just around the corner?
Not financial advice- do your own research

This AI Company is Up +270%

Earnings are forecast to grow 125.66% per year
Symbotic (NASD: SYM) is an AI-powered robotics startup that serves some of the world's largest retailers, including Walmart, Albertsons, and C&S Wholesale Grocers. Robots are used by the company's technology to pick, pack, and ship orders, which can help to enhance efficiency and cut costs.
The stock is on a tear this year with roughly 270% gains over the period and as much as 40% intraday.
The warehouse automation company's excellent financial performance, which blasted beyond even the most bullish projections, was the impetus that sent SYM stock soaring.
SYM has skyrocketed this year due to a number of factors, including:
Strong fiscal performance: In the third quarter of 2023, SYM reported revenue of $392 million, up 61% from the same quarter in 2022. The company also reported its first-ever adjusted profit of $13 million.
Growing demand for warehouse automation: As retailers face labour shortages and rising expenses, there is a growing demand for warehouse automation. SYM's technology is a tried-and-true solution that can assist merchants in meeting these problems.
Positive analyst sentiment: Analysts are enthusiastic on SYM stock, with several rating it as a "buy" or "strong buy," which has contributed to the stock's rise.
SYM is a promising stock with a promising future. The company is well-positioned to capitalise on the expanding demand for warehouse AI automation, and its outstanding financial success demonstrates its execution. Many people believe that SYM stock is a smart long-term investment.
Here are some specific reasons why SYM is so good at generating revenue:
Recurring revenue model: SYM's revenue is largely recurring, as it comes from software subscriptions and service contracts. This provides the company with a predictable stream of income.
High-margin business: SYM's gross margins are over 70%, which is very high for a technology company. This means that the company is able to keep a large portion of each dollar of revenue that it generates.
Long-term customer relationships: SYM has long-term customer relationships with some of the world's largest retailers. These relationships provide the company with a stable base of revenue.
I hope this information is helpful. Please let me know if you have any other questions.
The AI Advantage.
Symbotic is already heavily utilizing AI in its business model, but the company is continuously exploring new ways to integrate this powerful technology into its operations. Here are some specific examples of how SYM is using AI:
Warehouse optimization: The AI algorithms developed by Symbotic are used to optimise warehouse layouts, robot pathways, and order picking tactics. This contributes to ensuring that the company's systems run as efficiently as possible.
Predictive maintenance: Symbotic's AI models are used to predict when equipment is likely to fail. This allows the company to proactively schedule maintenance and avoid unplanned downtime.
The AI algorithms developed by Symbotic are used to optimize inventory levels and reduce the danger of stockouts. This contributes to the company's consumers always having the things they require.
Demand forecasting: Symbotic's AI models are used to forecast future demand for products. This helps the company to plan its production and staffing levels more effectively.
Symbotic is committed to using AI to further improve its products and services. The company believes that AI has the potential to make its systems even more efficient, reliable, and cost-effective.
Here are some additional examples of how SYM is trying to incorporate AI..
Developing new AI-powered applications: Symbotic is developing new AI-powered applications that can help retailers to improve their operations. For example, the company is developing an AI-powered system that can help retailers to optimize the use of their delivery trucks.
Symbotic is collaborating with other AI firms to develop new technologies that can be integrated into its platforms. For example, the company is collaborating with an artificial intelligence startup to create a system that can automatically identify and track things in warehouses.
Investing in AI research: Symbotic is investing in AI research to develop new AI algorithms and techniques that can be used to improve its systems. The company has a team of AI researchers who are working on a variety of projects, including developing new algorithms for robotic picking and packing.
SYM is a high-growth, high-potential stock, but it is also a young company with a limited track record. If you are willing to accept a higher level of risk, Symbotic could be a good long-term investment. However, if you are risk averse, you should wait for the company to mature before positioning.
NFADYOR- Not financial advice- do your own research

This Gene Editing Stock Could Be Worth Billions

Gene editing stocks are expected to be among the most attractive growth businesses with a significant impact on medicine and earnings between now and 2030.
Editas Medicine (NASD: EDIT) is working on a treatment for sickle cell disease (SCD) and other genomic medicines. The company's lead product candidate for SCD is EDIT-301, an investigational gene-editing therapy that is designed to increase the production of fetal hemoglobin (HbF) in patients with SCD. HbF is a type of hemoglobin that is normally produced in the womb and during early infancy, but it is not produced in adults with SCD. HbF does not sickle, which means that it does not change shape and become sticky when it releases oxygen. As a result, increasing the production of HbF can help to reduce the symptoms of SCD.
In November 2023, Editas Medicine announced positive initial safety and efficacy data from the first four patients treated in the RUBY trial, a Phase 1/2 clinical trial of EDIT-301 for the treatment of SCD. The data showed that EDIT-301 was well-tolerated and that it led to a sustained increase in HbF production in all four patients.
There will be a further update next month which could be a catalyst for the entire sector.
Editas Medicine is also developing EDIT-302, an investigational gene-editing therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT is a rare genetic blood disorder that is similar to SCD. Patients with TDT do not produce enough hemoglobin, and they require regular blood transfusions to survive. EDIT-302 is designed to increase the production of HbF in patients with TDT, which could reduce or eliminate their need for blood transfusions.
Editas Medicine is a leading company in the development of CRISPR-based gene-editing therapies for genetic diseases. The company's therapies have the potential to be transformative for patients with these diseases.
Comeback?
Wall Street experts who follow the biotechnology industry expect EDIT stock to make a comeback after reaching all-time highs only a few years ago. The average analyst forecasts a 42% increase in the stock over the next 12 months.
Experts are generally positive on EDIT stock, with an average analyst rating of "buy" and an average analyst price target of $15.00 per share. This suggests that analysts believe EDIT stock has the potential to outperform the market in the long term.
There are a number of reasons why EDIT stock could go up rapidly. First, EDIT-301 is the principal product candidate being tested by the business for the treatment of sickle cell disease (SCD) and Leber congenital amaurosis (LCA10). Phase 1/2 clinical trials for EDIT-301 are presently being conducted by Editas Medicine for both indications. If EDIT-301 is successful in clinical trials and commercialized, it could be a blockbuster drug with the potential to generate billions of dollars in revenue for the company.
Second, Editas Medicine is also working on treatments for other serious genetic diseases, including sickle cell disease and transfusion-dependent beta-thalassemia. These are also potentially large markets, and if Editas Medicine can develop successful treatments for these diseases, it could significantly boost the company's valuation.
Third, Editas Medicine is a leader in the development of CRISPR-based gene-editing therapies. CRISPR is a revolutionary new technology that has the potential to cure a wide range of genetic diseases. If Editas Medicine can continue to develop innovative CRISPR-based therapies, it could become a major player in the biotechnology industry.
Of course, there are some dangers involved in purchasing EDIT stock. The company's principal product candidate is still in clinical studies, and its success is not guaranteed. Furthermore, the biotechnology sector is highly competitive, with several other companies pursuing CRISPR-based medicines. These firms potentially threaten Editas Medicine's market share.
Overall, EDIT stock is a speculative investment with the potential for high returns. The company's lead product candidate has shown promise in early clinical trials, and the company has a strong pipeline of other potential therapies.
How will the stock perform on the December clinical results?
NFADYOR

This Stock Looks to Head Higher After Earnings Gain

Shares advanced +400% from lows set earlier this year.
Myomo, Inc. (MYO) has released earnings for the third quarter and nine months ending September 30, 2023. The company reported revenue of USD 5.08 million for the third quarter, up from USD 3.97 million the previous year. The nett loss was USD 2.03 million, down from USD 2.83 million the previous year. The basic loss per share from continuing operations was USD 0.06 in comparison to USD 0.4 the previous year. The diluted loss per share from continuing operations was USD 0.06 in comparison to USD 0.4 the previous year.
Revenue for the first nine months was USD 14.48 million, up from USD 11.51 million the previous year. The net loss was USD 5.69 million, down from USD 8.55 million the previous year. The basic loss per share from continuing operations was USD 0.21 in comparison to USD 1.24 the previous year. The diluted loss per share from continuing operations was USD 0.21 in comparison to USD 1.24 the previous year.
Recently, there has been an increasing trend in MYO earnings estimate revisions, which can be regarded a bullish indicator on the fundamental side. This is due to the fact that a favorable trend in earnings estimate revisions usually translates into price appreciation in the short term.
The company's stock price has been gaining in recent weeks, up 20% since the earnings report.
There are a few reasons for this:
The company's better-than-expected earnings report was a positive sign for investors.
The company is expanding its product line and international reach, which could lead to future growth.
The company's technology is being used in a growing number of clinical trials, which could lead to increased demand for its products.
Myomo, Inc. is a medical technology company that develops and markets powered arm braces for people with upper-limb paralysis. The company's flagship product is the MyoPro®, a lightweight, non-invasive brace that uses EMG signals to detect and amplify the user's own muscle activity. The MyoPro® has been shown to improve function and independence in people with a variety of neurological conditions, including stroke, spinal cord injury, and cerebral palsy.
In addition to the MyoPro®, Myomo is working on a new product pipeline that includes a pediatric arm brace and a brace for those with lower-limb paralysis. In addition, the company is investing in R&D to improve the performance of its existing products and to develop new technologies for the treatment of neurological diseases.
Myomo is a pioneer in the field of powered arm braces. The products of the company have the potential to greatly enhance the lives of those who have upper-limb paralysis. Myomo is well-positioned to expand further in the next years.
MYO presently has an analyst rank #2 (Buy), putting it in the top 20% of the more than 4,000 stocks ranked based on trends in earnings estimate revisions and EPS surprises. Stocks with a “Zacks” Rank of 1 or 2 typically outperform the market.
Looking at the MYO chart, we see a definite advance above the 200EMA, which is positive, followed by the formation of a support zone for the stock. MYO shares have already surged more than 110% since the beginning of the month and may reverse following such an aggressive move up. That said, most investors use a retrace to find better entry levels if the stock looks to maintain an upward trajectory.
Overall, Myomo is a small, growing company with a lot of potential. The company's recent earnings report and its expanding product line and international reach are positive signs for investors. However, the company is still facing some challenges, such as its history of losses and its reliance on government research funding. Investors should carefully consider these risks before investing in Myomo.
NFADYOR

This Early Stage Cancer Drug Company Pumped 59%

Cancer-focused Kinnate Biopharma Inc. (KNTE), which went public in the midst of a biotech industry boom in 2020, announced last month that it will reduce its personnel by 70% and cut down its cash burn significantly in order to extend development programs until 2026.
The business will halt development of an experimental solid tumor therapy, halt development of its lead anti-cancer drug exarabehib as a solo treatment, and instead focus on combining that drug with another therapeutic targeting solid tumors.
Exarafenib, the company's principal clinical candidate, is now being studied as a monotherapy and in combination with Pfizer's drug.
As part of its reprioritization activities, the corporation will also investigate strategic alternatives for the other development program under KIN-3248.
The reaction from the market turned positive with shares of KNTE gaining more than 110% in 3 trading sessions. Clearly the stock has broken out from an extended down trend and looks to be in a new market structure with shares gaining momentum.
There are a few possible reasons why KNTE stock has rallied recently, despite the company announcing workforce cuts and program streamlining.
-Investors may be betting that the company's cost-cutting measures will improve its financial position. By reducing its workforce and streamlining its programs, Kinnate Biopharma can save money and extend its cash runway. This could make the company more attractive to investors.
-Investors may be reacting positively to the company's focus on its lead product candidate. KNTE is now focusing all resources on developing a single cancer therapy and fast tracking its roadmap to approvals. This could be a good decision, as cancer therapeutics is a large and growing market with significant unmet needs.
-The overall market for biotech stocks may be recovering. The Nasdaq Biotechnology Index has been on an upward trend since the beginning of the year. This recovery in the overall market could be lifting KNTE stock along with it.
Here are some additional factors that investors may be considering:
-The company's management team has a strong track record of success.
-The company has a promising pipeline of other novel therapies in its portfolio.
-The company is well-positioned to benefit from the growing market for cancer treatments and the partnerships available.
Trimming operations.
The business announced that it is "separating from" every employee of its fully owned Chinese affiliate, Kinnjiu Biopharma, a joint venture founded in 2021 that Kinnate purchased in February for $24 million in cash and shares from Kinnate Series A investors OrbiMed and Foresite Capital Management.
KNTE anticipates filing an investigational new medication application with the Food and medication Administration in the fourth quarter (for the cancer-fighting medicine KIN-8741), the first step towards enrolling in a clinical study.
Kinnate's altered clinical pipeline leaves the business with only one clinical-stage development programme, the study of exarafenib with Mektovi in the treatment of advanced NRAS mutant melanoma. The study is also in its early stages, making it prone to failure. In the absence of an ongoing second clinical development program, any developmental or regulatory setback will be challenging for KNTE.
It is important to note that the recent stock rally in KNTE does not mean that the company's long-term prospects are guaranteed. The company still faces a number of challenges, including the need to possibly raise additional capital and the uncertainty of its clinical trials. Investors should carefully consider all risks before investing in KNTE stock.
Overall, the recent stock rally in KNTE is a positive sign for the company.
Will the rally continue or will this move fade back to lower levels?
NFADYOR

This Stock Ready to Explode

ACLS Stock Target $225
Axcelis Technologies (NASD: ACLS), a semiconductor service provider, is only worth $4.5 billion- Nonetheless, despite the challenging economic conditions that have caused many other semiconductor companies to experience slowdowns, ACLS has produced robust sales and earnings growth over the past 12 months.
Considered to be a top stock heading into 2024, ACLS boasts a strong track record and near flawless balance sheet:
-Trading at 32.7% discount of its estimated fair value.
-Earnings are expected to rise +10.47% per year.
-In the last year, earnings increased by 43.5%.
-Trading at good value in comparison to peers and the industry benchmark
Being essential to the manufacturing of semiconductors, Axcelis does not manufacture chips but rather it produces ion implantation machinery, which is essential to the manufacturing process. The company's one product line, Purion, continues to see high demand.
Power devices, which process and supply electricity in situations requiring large currents, are manufactured using this technology. Because the Purion line can produce large quantities of silicon carbide power devices, semiconductor companies that make electronics for the automotive industry are particularly fond of it at the moment.
The demand for semiconductor equipment is expected to grow in the coming years as the semiconductor industry continues to expand. This is due to the increasing demand for semiconductors in a wide range of applications, such as smartphones, computers, and data centers.
Axcelis's strong product portfolio: The company's products are used in a variety of semiconductor manufacturing processes, including ion implantation, epitaxial deposition, and thermal processing.
ACLS is also prepared for artificial intelligence (AI) to boost long-term demand for its equipment. According to the business, AI will necessitate processors with far greater memory (DRAM) and storage (NAND) capabilities than traditional hardware. That will be beneficial to its operations.
Strong Revenue Milestones
Despite a challenging economic slowdown and increased interest rates, ACLS has profited from strong demand in new and developing industries like as artificial intelligence and electric vehicles.
Axcelis is less vulnerable to short-term economic shocks since chipmakers frequently plan capital expenditures years in advance, and the company's equipment is included in such plans.
ACLS also boasts a $1.2 billion order backlog, which is equivalent to more than a full year's income. This means that the company has a robust pipeline of work heading into 2024 and should be well-positioned to profit from a market resurgence.
Experts are bullish:
Analysts anticipate that Axcelis Technologies (ACLS) will continue to perform well in 2024. The average 12-month stock price projection for ACLS shares is $178, implying a 35.31% gain from today’s prices. The lowest and highest targets are $145 and $225, respectively.
Looking at the chart for ACLS, you can see that it has just completed a good reset of the RSI on larger time periods and has found firm support at $135. This is frequently seen in stocks immediately before a significant breakout. Given the stock's bullish outlook and solid 12-month performance, it would not be surprising to see ACLS meet its target early next year.
Of course, there are also some risks to consider. For example, the semiconductor industry is cyclical, and there is always the possibility of a downturn. Additionally, ACLS faces competition from a number of other semiconductor equipment companies.
Overall, the outlook for Axcelis Technologies in 2024 is positive. The company is well-positioned to benefit from strong tailwinds in the semiconductor industry, and it has a strong product portfolio, a successful execution track record, and a compelling investment opportunity.
NFADYOR

TMDX Stock Advances 51%

On November 6, 2023, TransMedics Group Inc (NASDAQ:TMDX), a leading medical technology business, released its financial results for the third quarter ended September 30, 2023. Revenue increased significantly, owing principally to increased utilization of its Organ Care System (OCS) across all three products, as well as the addition of logistics and aviation revenue.
TransMedics revised their revenue projection for the entire year 2023 to be between $222 million and $230 million, which would represent a 138% to 146% increase over the company's previous year's sales. The business had previously projected revenue of $180 million to $190 million for 2023.
TransMedics is a medical technology firm in its commercial stage that is revolutionizing organ transplant therapy for patients with end-stage organ failure in various disease situations. TMDX created the Organ Care System, or OCS, to replace a long-standing medical protocol that severely restricts hundreds of thousands of patients' access to life-saving transplant medicine across the globe. Many features of the organ's normal living and functioning environment outside of the human body are replicated by cutting-edge OCS technology. Thus, organ preservation for transplantation is now a dynamic environment that facilitates new capabilities like organ optimization and assessment, thanks to a paradigm shift brought about by the OCS.
By revolutionizing the organ donation and transplant process, TMDX has swiftly become one of the more promising stocks to root for in biotech.
TransMedics went public in 2019 and has seen its shares climb more than 300% by mid 2023. However, its stock price has dropped by more than 55% in the previous three months as the market grappled with TransMedics' recent mergers and acquisitions (M&A) activities, having a near term negative impact.
TMDX worth the wait?
This has put investors in a challenging position. Is the corporation a falling narrative, reliant on M&A to gain value or is TMDX on the verge of revolutionizing the organ transplant industry and actively capitalizing on its first-mover advantage?
Solving a massive problem with donor transport...
Organs are kept alive throughout transportation using TransMedics Group's Organ Care System (OCS). More than 80% of donated hearts and lungs reached their recipients in clinical trials. The use of donor liver increased twofold. The overall rate of severe post-transplant problems dropped.
The fact that TransMedics does not own the full end-to-end logistical process associated with organ transplantation has been one of the main obstacles to its expansion. However, with the company's recent acquisition of Summit Aviation, a provider of charter flights, that will no longer be the case. Through this acquisition, TransMedics will be able to expand its own national organ transplant assistance air logistics network.
Despite the challenges, TMDX stock remains a promising investment for long-term investors. The company is addressing a significant unmet need in the organ transplantation market, and its OCS has the potential to revolutionize the way organs are transported and transplanted. If TransMedics is successful in commercializing its OCS, the company could become a major player in the organ transplantation market.
Here are some of the factors that could drive TMDX stock price higher in the future:
-Increased adoption of the OCS by transplant centers
-Approval of the OCS for the transportation of livers and kidneys
-Expansion of the National OCS Program
-Development of new products and services for organ transplantation
Here are some of the risks that could weigh on TMDX stock price in the future:
-Delays in commercializing the OCS
-Competition from other organ transport companies
-Reimbursement challenges from insurance companies
-Regulatory setbacks
Overall, TMDX stock is a high-risk, high-reward investment. The company has the potential to revolutionize the organ transplantation market, but it also faces significant challenges.
Will the rally continue or will the stock face more resistance from selling pressure/ short sellers?
NFADYOR- not financial advice do your own research

Ramaco Resources METC Stock Went Up 36%

The stock boards are beaming with speculation about recent events and subsequent share gain for Ramaco Resources Inc (NASD: METC) after the stock rallied more than 36% intra-day.
Some quick highlights:
-Trading 45.5% less than what we believe to be its fair value
-Earnings expected to grow 8.35% per year
-Trading at great value in relation to peers and the industry
Ramaco Resources raised its full-year 2023 coal shipping projection to 3.25 3.5 million tonnes, up from 3.1 3.6 million tonnes before. The business also offered an update on its Wyoming activities, including the start of mine development at the Brook Mine and a focus on two carbon product categories.
Overall, Ramaco Resources Inc (NASDAQ:METC) has shown resilience and growth in a difficult market by focusing on operational efficiency and strategic financial management. The company's enhanced guidance and continuous developments point to a bright future.
The CEO commented:
"Our third quarter results highlight our differentiated growth platform. In simple terms, this quarter Ramaco grew from being a company with a sales level of ~3 million tons to ~4 million tons per annum. As a result, Adjusted EBITDA grew over 50% from the second quarter, despite a decline in margins on the back of lower index pricing and market conditions," said Randall Atkins, Ramaco Resources Chairman and Chief Executive Officer.
More good news ahead?
Positive earnings outlook. Analysts are expecting Ramaco Resources to report strong earnings for the third quarter of 2023. This is due to a number of factors, including rising coal prices and increased demand for metallurgical coal.
Increased investment in coal stocks. Coal stocks have been performing well in recent months, as investors bet on a rebound in the coal industry. This is due to a number of factors, including the war in Ukraine, which has disrupted global energy markets.
Short squeeze. METC stock is heavily shorted, meaning that a large number of investors are betting that the stock price will go down. However, the recent positive news about the company has led to a short squeeze, as short sellers are forced to buy back shares to cover their losses. This is healthy in the near term, but investors should be wary of more short sellers entering the market now that prices have reached potentially overbought levels.

Despite these challenges, there are also some reasons to remain bullish on METC stock:
The company has a strong financial position. METC has a low debt-to-equity ratio and a healthy cash balance. This gives the company the financial flexibility to weather any challenges that the coal industry may face.
METC is well-positioned to benefit from rising coal prices. Coal prices have been rising in recent months due to the war in Ukraine and other factors. This is good news for METC, as it will increase the company's revenue and profitability.
METC is investing in the future. The company is investing in new coal mines and other projects to ensure its long-term growth.
Overall, there are both bullish and bearish arguments for METC stock. Investors should weigh the risks and rewards before making any investment decisions.
It is important to note that past performance is not indicative of future results. The stock market is volatile and unpredictable, and investors should always do their own research before making any investment decisions.

This Stock Dumped 46% in 7 Days

Rumors are hitting the street- Plug Power (NASD: PLUG) may declare bankruptcy if it does not raise extra funds in the next 12 months to stay afloat.
In a later filing with the Securities and Exchange Commission, Plug Power stated that, given its present financial situation and anticipated capital expenditures, there is "substantial doubt about the Company's ability to continue as a going concern."
Here is yet again another high profile stock that is facing huge challenges as a going concern after hitting all time highs just a few years ago.
PLUG is down 99% from 2020.
Immediate risks impacting the stock price:
-Less than 1 year of cash on hand
-Major insider selling in the last 3 months
-Shareholders have been diluted in the last year and should expect more dilutive funding in the future.
-High short interest sees PLUG down nearly 80% this year and almost 50% in a week
-Loss per share year over year down 57% from a year ago
PLUG is asking the Department of Energy for a $1.5 billion loan as part of the financing for its green hydrogen network, but money is unlikely to start coming until early in the upcoming year, if approved at all.
To further complicate the situation, the stock fall out means that most leverage opportunities to use equity as financing is likely off the table.
PLUG blames supply chain disruptions for the recent earnings miss.
Here are some additional details about the supply chain disruptions that Plug Power faced:
Shortages of key components: Plug Power said that it was experiencing shortages of key components, such as semiconductors and steel. These shortages were making it difficult to manufacture fuel cells and electrolyzers.
Transportation bottlenecks: Plug Power also said that it was facing transportation bottlenecks, which were making it difficult to ship its products to customers. These bottlenecks were caused by a shortage of truck drivers and labor shortages at ports.
Plug Power is hoping that the supply chain disruptions will ease in the coming months. However, the company is also taking steps to mitigate the impact of the disruptions, such as diversifying its supply chain and investing in automation.
This recent news is a striking contrast to just a few weeks ago when the company recently stated it may reach profitability by 2027 or sooner.
PLUG is inexpensive, according to experts who cover the stock, despite a deluge of bad news and a market crash. Even after downgrades and adjustments, PLUG has a stock price target of $11.38, which is more than 200% higher than current levels.
For the time being, PLUG maintains a healthy balance sheet with debt to equity ratio of 15%. Moreover, estimates report earnings are forecast to grow above the industry average and the stock is trading well below fair value.
Will PLUG get financing and turn this around?
For now the stock carries massive risks as a going concern and investors should conduct proper due diligence before considering PLUG.
NFADYOR

This Micro Cap Ripped 3972%
No it’s not a typo… Tempest Therapeutics (NASD: TPST), a battered down biotech stock with a portfolio of cancer treatment candidates, out of obscurity hits a four digit intra-day return on massive volume.
The message boards are on fire.
TPST released updated stats from its ongoing trials and the results were favorable.
You can view the press release here:
https://ir.tempesttx.com/news-releases/news-release-details/tempest-releases-new-data-demonstrating-superiority-tpst-1120
The company will also make a conference call recording of the event for listening on its website here:
https://ir.tempesttx.com/
Tempest Therapeutics is a clinical-stage oncology firm that is developing small compounds with the potential to cure a variety of tumors by combining tumor-targeted and immune-mediated processes. The business has a wide range of innovative programmes, from early research through analysis in a randomized international study including first-line cancer patients. The two unique clinical programmes from the business, TPST-1120 and TPST-1495, which respectively target PPAR and EP2/EP4, are moving forwards in trials meant to examine the drugs both alone and in combination with other licensed drugs. Additionally, Tempest is working on an orally absorbable TREX1 inhibitor. TREX1 is a target that regulates the activation of the cGAS/STING pathway.
Yesterday’s results were positive and showed that TPST-1120 was superior to the standard of care treatment, sorafenib, across multiple study endpoints.
In plain English, this means that TPST-1120 was more effective than sorafenib at shrinking tumors and prolonging survival in patients with first-line HCC.
Here is a less technical explanation of the results:
TPST-1120 shrank tumors in 47% of patients, compared to 34% of patients treated with sorafenib.
The median progression-free survival (PFS) was 8.3 months for patients treated with TPST-1120, compared to 5.6 months for patients treated with sorafenib.
The median overall survival (OS) was 12.2 months for patients treated with TPST-1120, compared to 9.3 months for patients treated with sorafenib.
In addition to being more effective, TPST-1120 was also better tolerated than sorafenib. Fewer patients treated with TPST-1120 experienced serious side effects, and the side effects that did occur were generally less severe.
Overall, the results of the Tempest Therapeutics first-line HCC study are very promising and suggest that TPST-1120 has the potential to be a new standard of care treatment for this deadly disease.
If we turn our attention to the stock we see a host of red flags that the company needs to address soon if it hopes to have continued support in the market from retail and institutional investors.
For example, a mediocre balance sheet, a stock price rated as overvalued, lack of adequate cash, and no meaningful revenue.
On the flip side, this is very common as a going concern for a biotech looking to hit it big with a handful of therapeutics to treat disease- In fact its more or less the norm.
Several analysts have also come out and stated their view with an average price target for TPST above $15.
So what happens next?
In all likely hood the stock will retrace after a move like this given the extent of the rally. Furthermore, short sellers are likely now paying attention to any weakness that comes after exaggerated rips like this- Lets see what happens in the coming days.
NFADYOR- not financial advice do your own research

This Stock Could Double in Value After Gaining 80%
Autolus Therapeutics (AUTL) is a biotech company that creates treatments that reprogram T lymphocytes in patients to attack cancer cells. It is currently trading at $4 per share but could be valued up to $8-$12.
The stock has risen in value from a low of $2 before gaining traction due to positive news and announcements.
AUTL is a clinical-stage biopharmaceutical company developing novel CAR-T cell therapies for the treatment of cancer. The company's lead product candidate, obe-cel, is in late-stage development for the treatment of acute lymphoblastic leukemia (ALL). Obe-cel has demonstrated promising results in clinical trials, and the company is planning to file a Biologics License Application (BLA) with the FDA by the end of 2023.
The company's other CAR-T cell therapies in development include AUTO8 for multiple myeloma and AUTO6NG for neuroblastoma. Autolus is also developing a proprietary platform for the discovery and development of novel CAR-T cell therapies.
Based on this information, it is possible that the stock price of Autolus Therapeutics could continue the current trajectory and go up in the near future. Investors should carefully consider all of the risks and potential rewards before investing in Autolus Therapeutics.
Is it all good?
Autolus Therapeutics is fundamentally what many investors may expect from a fledgling biotech business. The stock holds a lot of promise, but that promise is accompanied by a lack of overall outcomes. It receives negligible grant and licensing money while incurring quarterly losses in the tens of millions of dollars.
Although the company has a strong balance sheet and cash position, the stock recently had an earnings/loss miss, as the actual cash burn was higher than the forecasted number.
The CEO recently commented in a press release:
“The coming months will be an exciting and instrumental time for Autolus as we plan for our first BLA submission for obe-cel with the US FDA by year end and we continue with our preparatory activities for a planned commercial launch in 2024, pending the necessary regulatory approvals,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “The data we have observed to date in the FELIX study highlights the potential of obe-cel to deliver a high complete remission rate combined with low levels of immunotoxicity and excellent CAR T expansion and persistence in adult patients with relapsed/refractory ALL. We look forward to building on the positive data when we present longer term follow up and additional subgroup analysis data at ASH in December.”
Expected News Flow for AUTL:
Obe-cel BLA submission to FDA By end 2023
Obe-cel FELIX data at ASH December 2023
AUTO8 update (MCARTY) at ASH December 2023
AUTO6NG Phase 1 study start (MAGNETO) By end 2023
Obe-cel in autoimmune disease – Phase 1 Early 2024
Obe-cel filing for a MAA to EMA First half 2024
Biotech stocks are known for being tough to forecast. Positive news indicating continuous progress towards commercialization should lead investors to assume that share values will rise. That isn't always the case with this company, since favorable news about a pivotal trial earlier this year didn't move share prices. Nonetheless, due to its high upside potential, AUTL stock is considered a speculative bet. It's a risk, but it's significantly less risky than the other companies on our list.
NFADYOR – not financial advice, and the above contains forward looking statements

#news #nasdaq #dowjonestoday

ORTX Soars 95%
The weekly biotech headlines continue with news of another acquisition hitting the wires and breathing life into a battered market for NASDAQ: ORTX.
The British gene therapy company Orchard Therapeutics (ORTX), which uses stem cells to treat rare disease, is being acquired by the Japanese pharmaceutical giant Kyowa Kirin. Subject to shareholder approval, the transaction has a cash value of about $478 million.
Post deal close, ORTX will become a wholly owned subsidiary of Kyowa Kirin.
There are a few reasons why Kyowa Kirin might be interested in acquiring Orchard Therapeutics. First, Orchard Therapeutics is a leader in the development of stem cell gene therapy treatments for rare diseases. Gene therapy is a type of treatment that uses genes to correct or replace defective genes in order to treat disease. It is a relatively new field of medicine, but it has the potential to revolutionize the treatment of many diseases.
Second, Orchard Therapeutics has a number of promising stem cell and gene therapy candidates in its pipeline. Its lead product, Libmeldy, is a gene therapy treatment for metachromatic leukodystrophy (MLD), a rare and fatal neurological disorder. Libmeldy was approved by the European Commission in 2022, and it is expected to be approved by the US Food and Drug Administration in the near future.
Third, Orchard Therapeutics has a strong team of scientists and clinicians with expertise in gene therapy. Kyowa Kirin can leverage this expertise to accelerate the development of its own gene therapy pipeline.
With the help of a patient’s own genetically altered hematopoietic stem cells (HSCs), the gene therapy strategy developed by Orchard Therapeutics may be able to address the underlying cause of a genetic condition with just one injection. After closing, the acquisition would give Kyowa Kirin a leading position in the developing field of genetic medicine, giving it access to a portfolio of HSC gene therapies for serious diseases where the burden on patients, families, and society is great and current treatment options are scarce or nonexistent.
The company’s approach entails taking blood stem cells from a patient, genetically altering those cells, and then reintroducing the modified cells into the patient. Orchard believes that by doing this, the disease’s fundamental cause will be treated at once.
Bobby Gaspar, CEO of ORTX commented:
“This is an exciting opportunity designed to accelerate the realization of our shared vision of ending the devastation caused by severe genetic diseases and deliver life-changing value in medical care. We remain as true to our mission as ever, and joining Kyowa Kirin’s global network ensures we are well-resourced to progress anticipated commercialization of OTL-200 in the U.S., if approved, continue investing in initiatives aimed at accelerating Libmeldy growth in Europe, capitalize on opportunities for global expansion, as well as advance our next-in-line neurometabolic programs in MPS disorders and earlier-stage research programs. We look forward to collaborating with our new colleagues at Kyowa Kirin to fully unlock the curative potential of HSC gene therapy for the benefit of patients and society.”
With this acquisition, Kyowa Kirin will be able to effectively accelerate the development of Orchard Therapeutics’ next-generation MPS programmes as well as its other early research initiatives, such as a severe genetic form of Crohn’s disease and frontotemporal dementia (FTD), while also maximising the value of Libmeldy®. A number of promising biopharmaceutical candidates with the potential to provide life-changing value in medical care, including in therapeutic areas and indications where Kyowa Kirin has extensive experience, such as oncology and autoimmune diseases, will be able to be developed further with the help of Kyowa Kirin’s abilities, resources, and infrastructure.
This news is a “life raft” acquisition that should revive ORTX moving forward, after having faced a difficult few years on its own.
Orchard Therapeutics was a troubled stock before the acquisition by Kyowa Kirin. The stock had been declining for some time, and received several downgrades by analysts.
The acquisition by Kyowa Kirin is a win-win development for Orchard Therapeutics and its new Japanese partner. Kyowa Kirin is a large and well-established pharmaceutical company with the resources to help Orchard Therapeutics commercialize its stem cell products and develop its pipeline.
This article is not financial advice- please do your own research
BiotechNewsAcquisitionStock Market Tips

$ALPN Beats Expectations Gains 39%

Alpine Immune Sciences (NASD: ALPN), announced positive results which led to the stock gaining more than 39%.
The data showed that povetacicept was well-tolerated and demonstrated significant reductions in proteinuria (excess protein in the urine) and disease biomarkers.
What does this mean for the company?
The positive clinical data from the RUBY-3 study is a significant milestone for Alpine Immune Sciences and its lead drug candidate, povetacicept. The data provides evidence that povetacicept could be a safe and effective treatment for aGN, a currently underserved patient population.
If povetacicept is successful in later-stage clinical trials and approved by the FDA, it could represent a major breakthrough in the treatment of aGN. The company plans to begin a Phase 3 study of povetacicept in IgA nephropathy, the most common type of aGN, in the second half of 2024.
Overall, the initial clinical data from the RUBY-3 study is very positive and suggests that povetacicept has the potential to be a significant new treatment for aGN. This could lead to significant revenue opportunities for Alpine Immune Sciences in the future.
In addition to the potential commercial value of povetacicept, the positive clinical data could also lead to increased interest in Alpine Immune Sciences from investors and potential partners. The company is well-positioned to capitalize on this momentum and advance povetacicept through the development process.
ALPN situated in Seattle Washington, has a varied pipeline of clinical and preclinical prospects. Povetacicept, a potentially best-in-class dual BAFF/APRIL inhibitor in development for several autoimmune illnesses such as systemic lupus erythematosus, autoimmune glomerulonephritis, and autoimmune cytopenias, is the company's primary pipeline candidate. The RUBY-4 study of povetacicept in autoimmune cytopenias and the RUBY-3 study of povetacicept in autoimmune glomerulonephritis are still enrolling patients. The preliminary results of the RUBY-3 research are expected later this year and might be a significant catalyst for the company.
Zacks Upgrade...
Given that Alpine Immune Sciences, Inc. (ALPN) was recently upgraded to a Zacks Rank #1 (Strong Buy), investors may find this to be an attractive portfolio candidate. One of the most potent factors influencing stock prices is the higher trend in earnings projections, which is effectively reflected in this upgrade.
Fundamental to the Zacks rating system is a company's evolving earnings picture. For the current and upcoming years, the system analyses the Zacks Consensus Estimate, which is a consensus assessment of EPS projections from sell-side analysts covering the stock.
Alpine Immune Sciences, Inc. has been upgraded to a Zacks Rank #1, putting it in the top 5% of Zacks-covered stocks in terms of estimate revisions, meaning that the stock could rise in the short term.
Consensus estimates for ALPN show a target price above $18.29 which indicates they expect another 30-35% upside for the stock in the near term.
Looking at the chart for ALPN the stock has done well in 2023 overall, gaining more than 110% from the lows set in January. Although the previous 30days were mostly selling, the stock has completely reversed trend and looks to be testing previous highs.
Is this a key level to buy?
Here are some other names to look at in the same space as ALPN
Dyne Therapeutics Gene editing Phase 1/2 clinical trials
Edgewise Therapeutics Precision medicine Phase 1/2 clinical trials
Savara Pulmonary diseases Phase 3 clinical trials
Avid Bioservices Contract development Commercial
Vera Therapeutics Rare blood disorders Phase 3 clinical trials
Liquidia Respiratory diseases Commercial
Evolus Aesthetic medicine Commercial
NFADYOR- Please note that this is not financial advice, and you should always do your own research before investing in any stock.

$HUT Returned +400%

Hut 8 Mining Corp (HUT) is a Canadian publicly traded company that engages in the business of mining Bitcoin and other digital assets. It is one of the largest Bitcoin miners in North America, with a self-mining capacity of over 3.8 exa-hashes per second (EH/s).
As we get closer to a significant deadline with the imminent bitcoin halving, we need to take into account alternative investments in bitcoin miners like HUT.
Incredibly, HUT rallied from January lows and managed a massive +400% return before topping out in July and giving back 50%. This is a far superior return to bitcoin over the same time frame and represents a true alternative to investing in the underlying asset.
There are a number of reasons why some investors may prefer to buy Hut 8 over Bitcoin itself.
HUT is a company with a team of experienced professionals and a track record of success. Bitcoin, on the other hand, is a digital asset that is still technically a software program under development.
Although HUT is impacted by the price of Bitcoin, it also has other sources of income, such as the sale of its mining services to other businesses- HUT investment “risk” may be decreased by this diversification.
Since Hut 8 is a publicly traded company, it must adhere to more stringent financial reporting and governance standards than Bitcoin does. For some investors, this may make it a more appealing investment. In fact this alone is a critical paint point for institutions that require a certain regulatory framework for any bitcoin exposure.
Investing in Hut 8 can be a way to gain exposure to Bitcoin without having to directly own or store the cryptocurrency. This can be appealing to investors who are concerned about the security and complexity of owning Bitcoin. Again, as more company balance sheets start to include bitcoin, this should become increasingly crucial.
As investors we should also compare HUT to other miners and “special situations” like we have with Grayscale. (For the purposes of this writing, we won’t include direct rivals; but, in upcoming articles, we’ll spotlight other miners).

Hut 8 has a number of advantages over other Bitcoin miners, including:
Low-cost power: Hut 8 has access to low-cost hydroelectricity in Canada, which gives it a significant competitive advantage over miners in other jurisdictions. Arguably there are some other minority operators in remote regions however in terms of large scale miners, HUT stands out.
Efficient operations: Hut 8 has a team of experienced mining professionals and operates state-of-the-art mining facilities. This is the bread and butter of a company like HUT that stands to profit substantially as the underlying asset gains value.
Strong financial position: Hut 8 has a strong financial position, with a healthy balance sheet and positive cash flow. Not to mention a solid future outlook with forecast earnings year over year above 35%.
Strong Brand Name and Credibility: Management is often guest speaking on social networks/ media, providing valuable insight for the digital asset community. This gives the market a strong sense of credibility and strengthens the brand position as an industry leader.
The pretend ETF?
Grayscale is a digital asset investment company that offers a variety of products and services, including the Grayscale Bitcoin Trust (GBTC), which in theory competes with not only bitcoin but miners like Hut 8. GBTC is a trust that holds Bitcoin and allows investors to gain exposure to the price of Bitcoin without having to directly own or store the cryptocurrency.
Despite GBTC’s simplicity and over-the-counter purchase capability, there are some significant problems with the trust’s operations and the probable absence of the regulatory framework that an ETF would provide.
HUT Bullish news…
Here are some recent events:
February 2023: Hut 8 and US Bitcoin announced a merger of equals to create a pre-eminent digital asset mining, hosting, managed infrastructure operations, and High Performance Computing organization.
February 2023: Hut 8 advanced its goal of achieving carbon neutrality by 2025 through an innovative recycling program.
February 2023: Hut 8 provided an update on its North Bay Facility, which is expected to be completed in early 2024.
June 2023: Hut 8 CEO Jaime Leverton was a speaker at the Collision Conference in Toronto, where she discussed the future of artificial intelligence and Bitcoin.
August 2023: Hut 8 will be a sponsor at the Canaccord Genuity 43rd Annual Growth conference in Boston.
August 2023: Hut 8 will be a speaker at the Blockchain Futurist Conference in Toronto.
September 2023: Hut 8 will be a speaker at the Needham Virtual Crypto Conference.
The following analysts cover Hut 8 Mining Corp. and have issued price targets (CDN dollars) in the last 3 months:
Michael Nicholson | RBC Capital Markets | $4.78 | Buy
Doug Taylor | Canaccord Genuity | $4.25 | Hold
Kevin Reynolds | Stifel Nicolaus | $3.75 | Hold
The average price target for HUT is $4.26
It is important to note that analyst price targets are just estimates and should not be taken as financial advice. Investors should always do their own research and consult with a qualified financial advisor before making any investment decisions.
NFADYOR

This Stock Might Double

Value-oriented investors are constantly looking for stocks that are trading below their true worth. Marathon Digital Holdings Inc. (NASDAQ:MARA) is one such stock that deserves consideration.
The trend for MARA appears to strongly correspond with that of bitcoin, which shouldn’t be a surprise considering mining stocks often follow the underlying asset value by default.
To that end, MARA stock has had a turbulent year, vaulting up 350% before correcting by losing half its value.
Bitcoin is finally showing signs of a change in market sentiment, as the bear market may finally be coming to an end.
Marathon has average fundamentals, but a very promising future outlook. If Bitcoin continues to rise in value in the next few months, MARA stock may easily double if not triple from prices we see today. Despite the recent uptick, the stock’s open short interest remains high at approximately 28%.
This might be the perfect storm for a short squeeze…
Marathon Digital is a leading Bitcoin mining company. It owns and operates a fleet of over 19,000 Bitcoin miners, which gives it one of the highest hash rates in the world. Marathon also has a fair balance sheet, with adequate cash and Bitcoin on hand.
Here are some of the things that make MARA a good Bitcoin miner compared to other companies in the same sector:
High hash rate: Marathon has one of the highest hash rates in the world, which means that it is able to mine Bitcoin more efficiently and profitably than many of its competitors.
Marathon has been aggressively ramping up Bitcoin mining capacity (Increased Operational Hash Rate 173% August 2023 YTD).
The operational hash rate will increase to roughly 30 EH/s once the present expansion is finished. As a result, Marathon will be well-positioned for strong revenue and cash flow growth in the event that Bitcoin prices rise sharply. With the expected halving of Bitcoin in 2024, that seems inevitable. As a result, one of the stocks to monitor for a short-squeeze is MARA stock, which appears to be headed for a major surge.
Experienced management team: Marathon has an experienced management team with a proven track record in the Bitcoin mining industry.
Focus on sustainability: Marathon is committed to sustainability and is working to reduce its environmental impact. The company uses renewable energy to power its mining operations and is developing innovative ways to reduce its energy consumption.
Key Highlights:
-Self-owned and operated mining pool (MaraPool)
-Increased control and transparency of operations
-Utilizing proprietary firmware
-Enhanced fleet management and optimization
-Shorter curtailment times
-Improved temperature control and voltage protection
-Investing in leading edge Bitcoin mining ASICs
-Investing in next-gen ASIC technology providers
-Custom-built immersion solution
-Reduces miner maintenance
There are a few key reasons why someone might want to buy MARA stock over owning Bitcoin itself:
Leveraged exposure to Bitcoin: MARA stock price is closely correlated to the price of Bitcoin, but it is typically more volatile. This means that investors can gain leveraged exposure to Bitcoin by investing in MARA stock. For example, if the price of Bitcoin rises by 10%, MARA stock price might rise by 20%. This can be a good way for investors to amplify their returns without exposure to margin or leverage.
Potential for higher returns: MARA has the potential to generate higher returns than Bitcoin over the long term. This is because MARA is a business that is focused on mining Bitcoin. As the Bitcoin network grows and the demand for Bitcoin increases, MARA’s revenue and profits are likely to grow as well. This could lead to higher stock prices.
Diversification: Investing in MARA stock can be a good way to diversify your overall portfolio. By investing in a Bitcoin mining company, you are exposing yourself to the Bitcoin market without having to own Bitcoin directly. This can mitigate some risk associated with direct exposure to the underlying asset.
Of course there’s always a trade off somewhere and it wouldn’t be fair to say that MARA doesn’t have its share of risks.
Some of the potential pitfalls of buying MARA..
Business risk: Because MARA is a business, it is exposed to business risk like all other enterprises. Risks including those associated with competition, regulation, and technical improvements are included. MARA’s stock price can decline if it is unable to compete successfully or if it is subject to unfavorable legislation.
Counterparty risk: MARA has a sizable Bitcoin holding. The asset value of MARA will decrease if the price of Bitcoin decreases. Additionally, having stock in MARA entails both the possible liabilities and assets that the company may incur as a result of conducting business.
Now that Bitcoin is making a comeback, is it time to buy MARA?
Investors should always do their own research before making any investment decisions.
NFADYOR

ALXO Up 54% On Results
NASDAQ: ALXO, Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
That was the title of the most recent press release from ALXO.
ALX Oncology is a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism. CD47 is a protein that helps cancer cells evade the immune system. By blocking CD47, ALX Oncology’s therapies aim to help the immune system recognize and attack cancer cells.
ALXO recently announced positive clinical results for its lead development candidate, evorpacept, in patients with recurrent platinum-resistant ovarian cancer. In a Phase 2 investigator-sponsored trial, evorpacept was combined with liposomal doxorubicin and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. The study showed that evorpacept was well-tolerated and led to a high response rate, with 60% of patients achieving a partial or complete response.
These results are significant because recurrent platinum-resistant ovarian cancer is a very difficult-to-treat disease. Patients with this type of cancer often have very few treatment options available to them. Evorpacept could potentially provide a new and effective treatment option for these patients.
It is important to note that these results are from a small Phase 2 study, and further research is needed to confirm the efficacy and safety of evorpacept in a larger population of patients. However, these early results are very encouraging and suggest that evorpacept could be a promising new treatment for recurrent platinum-resistant ovarian cancer.
In plain English, this means that people with recurrent platinum-resistant ovarian cancer may have a new treatment option that could help them live longer and better. Evorpacept is still in clinical development, but these early results are very promising.
Keun Wook Lee, M.D., Ph.D., Professor at Seoul National University College of Medicine and ASPEN-06 Principal Investigator, had this comment:
“These data in gastric cancer represent the first positive initial result in a randomized trial setting of blocking the CD47 immune checkpoint pathway with a CD47 blocker that has an inactive Fc effector function in order to treat patients living with advanced gastric cancer. Patients with advanced disease face poor outcomes following progression on initial treatment with HER2-directed therapy. Evorpacept could represent a breakthrough in therapy and a potential paradigm shift in the gastric cancer care continuum.”
Please view the full release here:
https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-positive-interim-phase-2-aspen-06-clinical
Today’s news is fairly significant and the stock price reflected that. If you look at the chart for ALXO on the weekly, the stock has completed a double bottom and now looks to be headed upward off news. Clear divergence can be seen and should be a catalyst for a move to reclaim previous failed support levels (much higher).
ALXO stock is promising and its partnerships also reflect that.
The biotech space is heating up and news of acquisitions/mergers and subsequent stock price rallies are the norm right now.
Here are some other big biotechs working with ALXO:
In June 2021, ALX Oncology announced a collaboration with Lilly to evaluate ALX148, its CD47-targeting antibody, in combination with Lilly’s CYRAMZA® (ramucirumab), trastuzumab, and paclitaxel in patients with gastric or gastroesophageal junction cancer.
This collaboration is significant because it will allow ALX Oncology to evaluate ALX148 in combination with a well-established and effective treatment regimen for gastric cancer. If the combination is shown to be safe and effective, it could provide a new and more effective treatment option for patients with this difficult-to-treat disease.
ALX Oncology is also working with other big biotechs, such as Bristol Myers Squibb, to evaluate ALX148 in combination with their respective cancer therapies. These collaborations are important because they allow ALX Oncology to evaluate ALX148 in combination with a variety of different cancer therapies, which could help to identify the most effective and tolerable treatment regimens for patients with different types of cancer.
Is this a good time to load up?
NFADYOR- not financial advice do your own research
#stocks #money #news

Metropolis Raises $1.7B
The AI narrative continues with news of SP Plus Corp (NASDAQ: SP) being bought by artificial intelligence company Metropolis and its computer vision platform.
Shares of SP stock rocketed nearly 45% during intra-day trading when news hit the wire.
This move certainly checks the box for strategic acquisition with SP being a major industry leader with an expansive network.
It must be noted that the transaction is subject to shareholder approval and antitrust clearance before closing. When the deal is finalized in 2024, SP+ will merge with Metropolis and run as a privately-owned business, assuming the necessary approvals are granted. The two businesses will remain totally separate and carry on as usual until and unless the merger closes.
Metropolis produces and deploys cutting-edge computer vision technology to give customers a “drive in and drive out” payment experience while enhancing transparency, collecting payments, and cutting costs for property owners. Up to this point, Metropolis has concentrated on implementing this checkout-free AI technology in its managed parking facilities, allowing premium real estate owners in more than 40 significant U.S. metropolitan areas to profit from the more than five million customers who do not have to stop-to-pay.
Best-in-class technology and operations management provider SP+ has a long history of merging cutting-edge technologies with first-rate support. In addition to managing almost two million parking spaces, SP+ employs more than 20,000 team members who work at more than 3,300 business locations and 160 airports. SP+ provides clients with a strong value proposition and the option to adopt technology upgrades that allow for seamless transactions through its Sphere Commerce technology solutions.
A win-win for both…
The goal of Metropolis and SP+ is to increase efficiency while enhancing the customer experience. With operations in more than 360 locations, serving millions of customers, and processing more than $4 billion in payments annually, Metropolis’ leading network in North America will be able to benefit from the gain of additional capabilities thanks to the acquisition of SP+. There are now more opportunities for property owners and managers to increase value, decrease inefficiencies and improve operations thanks to the growing market for checkout-free payment experiences.
Marc Baumann, Chairman and Chief Executive Officer of SP commented:
“This transaction delivers immediate and certain value to our stockholders at a substantial premium to current and historical trading levels. We expect the transaction to offer an exciting path forward for our team members, partners, clients and consumers in the U.S. and abroad. While our technology offerings are successfully fulfilling client and market demand, with increased investment, we see the opportunity to accelerate the technology roadmap for the benefit of our clients and their customers. Combining with Metropolis will advance the pace of technology deployment, which will allow us to do more for existing clients and add new ones as we provide additional high-quality, cutting-edge client and consumer experiences.”
Deal terms…
Shareholders of SP Plus Corporation will receive $54.00 in cash per share, which is 52% more than the stock’s closing price on October 4, 2023, and 28% more over the 52-week high.
In order to execute the acquisition, Metropolis has secured commitments for equity and debt financing totaling $1.7 billion, made up of $650 million in loan financing and $1.05 billion in financing for Series C preferred shares. Eldridge and Metropolis investor 3L Capital, as well as new investors Temasek, Vista Credit Partners, and related credit funds of BDT & MSD Partners, are leading these financial commitments. Slow Ventures and Assembly Ventures, two other current investors, also took part. While keeping a sizable amount of capital on its balance sheet, Metropolis will use the net proceeds to finance the purchase of SP+.
Expansive network ahead..
As Metropolis and SP will begin to roll out its tested technology, there is even more opportunity to offer checkout-free transaction experiences at even more places people go. The computer vision platform enables people to transact in the physical world with even greater ease than they experience online- From gas and electric vehicle-charging stations to drive-thrus and car washes, as well as retail stores.
Metropolis has also previously revealed a partnership with Uber to launch Uber Park from its platform to guide staffing, pricing, and maintenance at parking facilities. It also collaborates with nearby companies like supermarkets, coffee shops, and other merchants for in-app promotions.
Although this deal is a huge win for shareholders in SP, with the stock now topping out at the acquisition price, is it time to look for the next double digit stock before the end of 2023?
NFADYOR- not financial advice do your own research

PNT Up 84%... Buy?
Eli Lilly and Company (NYSE: LLY) and POINT Biopharma Global, Inc. (NASDAQ: PNT) today announced a definitive agreement for Lilly to acquire POINT for approximately $1.4B.
The deal will see Lilly launch a tender offer to buy all of the outstanding shares of POINT for $12.50 per share in cash (a total of about $1.4 billion), which is due at close. The board of directors of both firms have given their approval for the deal.
Subject to usual closing conditions, such as the tender of a majority of the existing shares of POINT’s common stock and license transfer permission from the U.S. Nuclear Regulatory Commission, the deal is not contingent on financing and is anticipated to close around the end of 2023. Any shares of POINT that are not tendered in the tender offer will be acquired by Lilly through a second-step merger at the same price as that charged in the tender offer after the tender offer has been successfully closed.
The stock reacted in a big way today after the news broke out and shares of PNT gapped up more than 84% intraday. Investors are scrambling to buy up shares before the deal closes.
Is this a good deal for Lilly stockholders and is it too late for investors to buy PNT?
Whether or not the Lilly acquisition of Point Biopharma is a good deal for investors depends on a number of factors, including their investment horizon, risk tolerance, and the performance of Point Biopharma’s pipeline of radioligand therapy candidates.
On the one hand, the deal gives Lilly access to a promising new clinical technology with the potential to revolutionize cancer treatment. Radioligand therapies are more precise than traditional chemotherapy drugs, and they can be used to target tumors that are difficult to reach with other therapies. Point Biopharma has two radioligand therapy candidates in late-stage clinical trials, and if these trials are successful, they could become blockbuster drugs.
With that said, Point Biopharma is still a relatively early-stage company, and its pipeline is still unproven. There is no guarantee that any of its radioligand therapy candidates will be successful, or that they will be approved by regulators (the biggest hurdle for any biotech). Additionally, the acquisition price of $1.4 billion is a significant premium to Point Biopharma’s pre-deal market capitalization, considering the stock had fallen down the chart in recent weeks. This suggests that Lilly is betting big on the potential of radioligand therapies, and that investors should be prepared for some volatility in the stock price in the near term.
As for whether there is any upside left for people who buy Lilly stock in the coming weeks, that is difficult to say. The stock price has already risen sharply in response to the acquisition announcement (PNT gap up +84%), and it is possible that most of the upside has already been priced in. However, if Point Biopharma’s late-stage clinical trials are successful, and if Lilly is able to successfully commercialize its radioligand therapy candidates, the stock price could still rise significantly.
Overall, investors should carefully consider their investment horizon, risk tolerance, and the performance of Point Biopharma’s pipeline before buying Lilly stock in the coming weeks.
Here are some additional things to consider:
Lilly is a well-established and well-respected pharmaceutical company with a strong track record of success. This gives investors some comfort that Lilly will be able to successfully commercialize Point Biopharma’s radioligand therapy candidates, if they are successful in clinical trials.
The acquisition of Point Biopharma is a strategic move by Lilly to expand its oncology capabilities into a promising new area of drug development. This could position Lilly to be a leader in the field of radioligand therapies in the future.
Following today’s news, it could be worthwhile to take a look at the other names listed next to PNT and add them to your watchlist. We may see short term volatility and a possible reaction in the sector.
Here are some other stocks in the same field or therapies as Point Biopharma (PNT):
Novartis (NVS): Novartis is a large pharmaceutical company with a significant presence in the oncology space. The company has a number of radioligand therapy candidates in development, including Pluvicto, which is currently in Phase 3 clinical trials for the treatment of prostate cancer.
Bayer (BAYRY): Bayer is another large pharmaceutical company with a number of oncology drugs in its pipeline. The company has two radioligand therapy candidates in Phase 2 clinical trials, including BAY 2502 and BAY 9403.
Arcus Biosciences (RCUS): Arcus Biosciences is a clinical-stage biotechnology company focused on developing radioligand therapies for cancer. The company has two radioligand therapy candidates in Phase 1 clinical trials, including ARC-731 and ARC-417.
Progenics Pharmaceuticals (PGNX): Progenics Pharmaceuticals is a clinical-stage biotechnology company focused on developing radioligand therapies for cancer. The company has two radioligand therapy candidates in Phase 3 clinical trials, including 177Lu-PSMA-617 and 177Lu-PSMA-I&T.
Capricor Therapeutics (CAPR): Capricor Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for cancer and other diseases. The company has a radioligand therapy candidate in Phase 1 clinical trials for the treatment of prostate cancer.
All of these companies are developing radioligand therapies for cancer, have radioligand therapy candidates in clinical trials, or have recently completed clinical trials. Moreover, all of these companies have a significant focus on radioligand therapy development, in direct competition to PNT.
These are just a few of the many companies that are developing radioligand therapies for cancer. The field is still relatively new, but there is a lot of excitement about the potential of these therapies to revolutionize cancer treatment.
Please do your own research and consult with an advisor before deploying any capital.
BuyoutMergers And AcquisitionsStock Market

How to Gain an Edge in the Stock Market with StockReporter

StockReporter is a powerful stock market screening tool that can help you identify the next breakout stocks. With StockReporter, you can:

Access a vast database of stock market data
Use advanced screening tools to identify stocks that meet your criteria
Get in-depth research reports on individual stocks
Track your portfolio performance and make informed trading decisions

Here are a few specific ways that you can use StockReporter to gain an edge in the stock market:

Identify breakout stocks

Breakout stocks are stocks that are poised to make a big move. They are typically characterized by unusually high trading volume and increasing prices. StockReporter's screening tools can help you identify breakout stocks with ease. We also cover breakdowns, which can be just as rewarding in terms of profit potential.

Invest in trending stocks

Trending stocks are stocks that are gaining popularity and attention from investors on several social channels simultaneously. StockReporter can help you identify trending stocks by tracking social media sentiment, news articles, and other factors.

Find undervalued stocks

Undervalued stocks are stocks that are trading below their intrinsic value. StockReporter's research reports can help you identify undervalued stocks with strong growth potential.

Make informed trading decisions

StockReporter provides you with all the information you need to make informed trading decisions. With StockReporter, you can track your portfolio performance, analyze market trends, and get research reports on individual stocks.

How to get started with StockReporter

Getting started with StockReporter is easy. Simply create an account and start using the screening tools to find stocks that meet your criteria. You can also read the in-depth research reports on individual stocks to learn more about the companies and their investment potential.

StockReporter is a powerful tool that can help you gain an edge in the stock market. By using the screening tools, research reports, and portfolio tracking tools, you can make informed trading decisions and increase your chances of success.

Here are some additional tips for using StockReporter to gain an edge:

Use the screening tools to create a watchlist of stocks that meet your criteria. This will allow you to easily track the performance of these stocks and be notified when they are ready to break out.
Read the article reports on individual stocks to learn more about the companies and their investment potential. This will help you make informed trading decisions.
Track your portfolio performance and analyze market trends with StockReporter's tools. This will help you identify areas where you can improve your investment strategy.

By following these tips, you can use StockReporter to gain an edge in the stock market and make profitable investments.

*Please read our disclaimer below for proper guidance when using StockReporter

Trade Ideas Delivered to Your Inbox
Real-Time Information For Timely Execution
Insight For Smart Money Investing Principles and Risk Management

We do the work for you

In-depth market research with our stock screening reports. Spend more time and effort executing profitable transactions rather than sifting through countless amounts of data with less profit.

Let the data do the work for you...

stocks featured on

OUR NEW PORTFOLIO MANAGEMENT TOOL IS NOW LIVE!

CLICK THE CHAT BELOW TO RECIEVE INSTRUCTIONS AND ACCESS THE SAME TOOLS THAT MADE OUR INSIDERS 692%

Page updated

Google Sites

Report abuse

GAIN YOUR MARKET EDGE

No Bias Only Data

We do the work for you

In-depth market research with our stock screening reports. Spend more time and effort executing profitable transactions rather than sifting through countless amounts of data with less profit.

Disclaimer